[시장보고서]ACE 억제제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 약물별, 제형별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

ACE 억제제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 약물별, 제형별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

ACE Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Drug, By Dosage Form, By Application, By End user, By Region and Competition, 2020-2030F

상품코드 : 1878842

리서치사 : TechSci Research

발행일 : 2025년 11월

페이지 정보 : 영문 182 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,681,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 8,165,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,877,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 안지오텐신 전환효소(ACE) 억제제 시장은 2024년에 69억 4,000만 달러로 평가되었으며, 2030년까지 CAGR 5.75%로 성장하여 97억 1,000만 달러에 달할 것으로 예측됩니다.

안지오텐신 전환효소(ACE) 억제제는 주로 혈관을 이완시키고 혈압을 낮춰 고혈압, 심부전, 만성신장질환 등의 질환을 관리하기 위해 사용되는 약물의 일종입니다. 이 억제제 시장은 전 세계적으로 심혈관질환 및 고혈압 유병률의 증가와 고령화 인구의 증가에 의해 주도되고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	69억 4,000만 달러
시장 규모 : 2030년	97억 1,000만 달러
CAGR : 2025-2030년	5.75%
가장 빠르게 성장하는 부문	경구 정제
최대 시장	북미

주요 시장 촉진요인

주요 시장 과제

주요 시장 동향

시장 규모 및 예측
- 금액별
시장 점유율과 예측
- 유형별(설프하이드릴 함유제, 디카르복실산 함유제, 포스폰산 함유제)
- 약물별(라미프릴, 에날라프릴, 베나제프릴, 포시노프릴, 캡토프릴, 모엑시프릴, 기타)
- 제형별(경구 정제, 경구 액제)
- 용도별(심부전, 만성 신장병, 고혈압, 당뇨병, 심근경색, 기타)
- 최종사용자별(병원, 온라인 약국, 기타)
- 지역별
- 기업별(2024)
시장 맵

제6장 북미의 ACE 억제제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코

제7장 유럽의 ACE 억제제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인

제8장 아시아태평양의 ACE 억제제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 일본
- 한국
- 호주

제9장 중동 및 아프리카의 ACE 억제제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
- 사우디아라비아
- 아랍에미리트
- 남아프리카공화국

제10장 남미의 ACE 억제제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
- 브라질
- 콜롬비아
- 아르헨티나

제11장 시장 역학

성장 촉진요인
과제

제12장 시장 동향과 발전

인수합병
제품 출시
최근 동향

제13장 세계의 ACE 억제제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협

제15장 경쟁 구도

Pfizer Inc
Novartis AG
Johnson & Johnson
Merck KGaA
Sanofi S.A
Bayer AG
United Therapeutics Corporation
Teva Pharmaceutical Industry
Bristol-Myers Squibb
Takeda Pharmaceuticals Company

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

KSM

영문 목차

영문목차

The Global ACE Inhibitors Market, valued at USD 6.94 Billion in 2024, is projected to experience a CAGR of 5.75% to reach USD 9.71 Billion by 2030. Angiotensin-converting enzyme (ACE) inhibitors constitute a class of pharmaceutical agents primarily utilized to relax blood vessels and reduce blood pressure, thereby managing conditions such as hypertension, heart failure, and chronic kidney disease. The market for these inhibitors is principally driven by the rising global prevalence of cardiovascular diseases and hypertension, alongside an expanding aging population.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.94 Billion
Market Size 2030	USD 9.71 Billion
CAGR 2025-2030	5.75%
Fastest Growing Segment	Oral Tablets
Largest Market	North America

Key Market Drivers

The increasing global burden of cardiovascular diseases represents a fundamental driver for the ACE inhibitors market. The widespread prevalence of conditions such as hypertension and heart failure necessitates effective and accessible therapeutic options. These illnesses not only reduce quality of life but also place substantial strain on healthcare systems worldwide. According to the "Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023" published in JACC, in September 2025, the number of prevalent cases of cardiovascular disease reached 626 million globally in 2023, underscoring the vast and growing patient population requiring management for these conditions. This elevated disease burden directly fuels the demand for ACE inhibitors, which are cornerstone treatments for various cardiovascular ailments, driving sustained market expansion.

Key Market Challenges

The potential for adverse effects associated with angiotensin-converting enzyme (ACE) inhibitors presents a significant impediment to market expansion. These side effects, including persistent cough, hyperkalemia, and rare angioedema, frequently lead to patient non-adherence or complete discontinuation of therapy. Such reactions directly diminish the patient base that continues to utilize ACE inhibitor treatments. According to research published in *Frontiers in Cardiovascular Medicine* in 2023, approximately 23.0% of patients prescribed ACE inhibitors were non-persistent with their treatment. This substantial rate of non-persistence, often influenced by the challenges of managing adverse drug reactions, directly limits the therapeutic lifespan of ACE inhibitors for individual patients.

Key Market Trends

The growing adoption of fixed-dose combination therapies represents a pivotal trend in the Global ACE Inhibitors Market. These single-pill combinations enhance patient adherence by simplifying complex treatment regimens, which is crucial for managing chronic conditions like hypertension and heart failure. Such formulations improve therapeutic outcomes by ensuring consistent medication intake. For instance, according to a study published in *J Clin Hypertens (Greenwich)* in August 2025, patients receiving angiotensin-converting enzyme inhibitor or angiotensin receptor blocker combination therapies exhibited the highest adherence rate at 79.18% in 2022-2023, compared to other antihypertensive drug classes. This improvement in adherence directly contributes to better disease control and sustained demand for ACE inhibitor-inclusive fixed-dose combinations.

Key Market Players

Pfizer Inc
Novartis AG
Johnson & Johnson
Merck KGaA
Sanofi S.A
Bayer AG
United Therapeutics Corporation
Teva Pharmaceutical Industry
Bristol-Myers Squibb
Takeda Pharmaceuticals Company

Report Scope:

In this report, the Global ACE Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

ACE Inhibitors Market, By Type:

Sulfhydryl-containing Agents
Dicarboxylate-containing Agents.
Phosphonate-containing Agents

ACE Inhibitors Market, By Drug:

Ramipril
Enalapril
Benazepril
Fosinopril
Captopril
Moexipril
Others

ACE Inhibitors Market, By Dosage Form:

Oral Tablets
Oral Solutions

ACE Inhibitors Market, By Application:

Heart Failure
Chronic Kidney Disease
Hypertension
Diabetes
Heart Attack
Others

ACE Inhibitors Market, By End user:

Hospitals
Online Drug Stores
Others

ACE Inhibitors Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global ACE Inhibitors Market.

Available Customizations:

Global ACE Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global ACE Inhibitors Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents., Phosphonate-containing Agents)
- 5.2.2. By Drug (Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others)
- 5.2.3. By Dosage Form (Oral Tablets, Oral Solutions)
- 5.2.4. By Application (Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Others)
- 5.2.5. By End user (Hospitals, Online Drug Stores, Others)
- 5.2.6. By Region
- 5.2.7. By Company (2024)
5.3. Market Map

6. North America ACE Inhibitors Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Drug
- 6.2.3. By Dosage Form
- 6.2.4. By Application
- 6.2.5. By End user
- 6.2.6. By Country
6.3. North America: Country Analysis
- 6.3.1. United States ACE Inhibitors Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Drug
    - 6.3.1.2.3. By Dosage Form
    - 6.3.1.2.4. By Application
    - 6.3.1.2.5. By End user
- 6.3.2. Canada ACE Inhibitors Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Drug
    - 6.3.2.2.3. By Dosage Form
    - 6.3.2.2.4. By Application
    - 6.3.2.2.5. By End user
- 6.3.3. Mexico ACE Inhibitors Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Drug
    - 6.3.3.2.3. By Dosage Form
    - 6.3.3.2.4. By Application
    - 6.3.3.2.5. By End user

7. Europe ACE Inhibitors Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Drug
- 7.2.3. By Dosage Form
- 7.2.4. By Application
- 7.2.5. By End user
- 7.2.6. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany ACE Inhibitors Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Drug
    - 7.3.1.2.3. By Dosage Form
    - 7.3.1.2.4. By Application
    - 7.3.1.2.5. By End user
- 7.3.2. France ACE Inhibitors Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Drug
    - 7.3.2.2.3. By Dosage Form
    - 7.3.2.2.4. By Application
    - 7.3.2.2.5. By End user
- 7.3.3. United Kingdom ACE Inhibitors Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Drug
    - 7.3.3.2.3. By Dosage Form
    - 7.3.3.2.4. By Application
    - 7.3.3.2.5. By End user
- 7.3.4. Italy ACE Inhibitors Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Drug
    - 7.3.4.2.3. By Dosage Form
    - 7.3.4.2.4. By Application
    - 7.3.4.2.5. By End user
- 7.3.5. Spain ACE Inhibitors Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Drug
    - 7.3.5.2.3. By Dosage Form
    - 7.3.5.2.4. By Application
    - 7.3.5.2.5. By End user

8. Asia Pacific ACE Inhibitors Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Drug
- 8.2.3. By Dosage Form
- 8.2.4. By Application
- 8.2.5. By End user
- 8.2.6. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China ACE Inhibitors Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Drug
    - 8.3.1.2.3. By Dosage Form
    - 8.3.1.2.4. By Application
    - 8.3.1.2.5. By End user
- 8.3.2. India ACE Inhibitors Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Drug
    - 8.3.2.2.3. By Dosage Form
    - 8.3.2.2.4. By Application
    - 8.3.2.2.5. By End user
- 8.3.3. Japan ACE Inhibitors Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Drug
    - 8.3.3.2.3. By Dosage Form
    - 8.3.3.2.4. By Application
    - 8.3.3.2.5. By End user
- 8.3.4. South Korea ACE Inhibitors Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Drug
    - 8.3.4.2.3. By Dosage Form
    - 8.3.4.2.4. By Application
    - 8.3.4.2.5. By End user
- 8.3.5. Australia ACE Inhibitors Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Drug
    - 8.3.5.2.3. By Dosage Form
    - 8.3.5.2.4. By Application
    - 8.3.5.2.5. By End user

9. Middle East & Africa ACE Inhibitors Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Drug
- 9.2.3. By Dosage Form
- 9.2.4. By Application
- 9.2.5. By End user
- 9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia ACE Inhibitors Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Drug
    - 9.3.1.2.3. By Dosage Form
    - 9.3.1.2.4. By Application
    - 9.3.1.2.5. By End user
- 9.3.2. UAE ACE Inhibitors Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Drug
    - 9.3.2.2.3. By Dosage Form
    - 9.3.2.2.4. By Application
    - 9.3.2.2.5. By End user
- 9.3.3. South Africa ACE Inhibitors Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Drug
    - 9.3.3.2.3. By Dosage Form
    - 9.3.3.2.4. By Application
    - 9.3.3.2.5. By End user

10. South America ACE Inhibitors Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Drug
- 10.2.3. By Dosage Form
- 10.2.4. By Application
- 10.2.5. By End user
- 10.2.6. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil ACE Inhibitors Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Drug
    - 10.3.1.2.3. By Dosage Form
    - 10.3.1.2.4. By Application
    - 10.3.1.2.5. By End user
- 10.3.2. Colombia ACE Inhibitors Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Drug
    - 10.3.2.2.3. By Dosage Form
    - 10.3.2.2.4. By Application
    - 10.3.2.2.5. By End user
- 10.3.3. Argentina ACE Inhibitors Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Drug
    - 10.3.3.2.3. By Dosage Form
    - 10.3.3.2.4. By Application
    - 10.3.3.2.5. By End user

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global ACE Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Pfizer Inc
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Novartis AG
15.3. Johnson & Johnson
15.4. Merck KGaA
15.5. Sanofi S.A
15.6. Bayer AG
15.7. United Therapeutics Corporation
15.8. Teva Pharmaceutical Industry
15.9. Bristol-Myers Squibb
15.10. Takeda Pharmaceuticals Company